Alderan

Quick links to important sections

Alderan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alderan

The following information establishes the identity, composition, and general mechanism of Alderan, strictly excluding details on dosage, specific therapeutic indications, or safety protocols.

Property Description
Active ingredient Losartan potassium
Form Film-coated tablet (for oral use)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common purpose Antihypertensive effect (blood pressure lowering)
Origin Synthetic compound

The Identity and Composition of Alderan

Alderan is a prescription-only medicinal product whose active ingredient is Losartan potassium, typically supplied as a film-coated tablet designed for oral administration. The Losartan compound is a synthetic, non-peptide molecule, meaning its active substance is manufactured rather than derived directly from natural sources. This preparation is a single active substance product (monotherapy), containing Losartan potassium along with pharmaceutical excipients that establish the tablet's structure.

Alderan's Pharmacological Class: Angiotensin II Receptor Blocker (ARB)

Alderan is definitively classified as an Angiotensin II Receptor Blocker (ARB), also known as an Angiotensin II Receptor Antagonist. This pharmacological class is clinically recognized for its targeted interaction within the body's cardiovascular regulatory system.

The active substance, Losartan potassium, is a widely researched and adopted ARB. It distinguishes itself from older medications in related classes, such as ACE inhibitors, by directly targeting the AT₁ receptors without the enzymatic inhibition mechanism.

General Antihypertensive Benefit

The general purpose of this medication is to achieve a consistent antihypertensive effect. This is accomplished by a precise blocking action that prevents the potent hormone Angiotensin II from binding to receptors in blood vessels. By preventing this binding, the vessels are allowed to relax and widen. This mechanism is typically used to provide long-term support for the cardiovascular system.

Regulatory References

  1. Angiotensin II Receptor Blockers (ARBs)

What side effects are possible with Alderan?

Possible Side Effects and Safety Information

The officially documented safety profile for Alderan (Losartan potassium) is structured by classifying adverse reactions based on their frequency and the physiological system affected, according to government regulatory standards. These classifications reflect findings from clinical trials and post-marketing surveillance.

Adverse Reactions by Frequency

Adverse effects are grouped into categories such as Common (may affect up to 1 in 10 people) and Uncommon (may affect up to 1 in 100 people).

Commonly documented adverse reactions often involve the nervous system (e.g., dizziness, headache, vertigo) and general disorders (fatigue, asthenia). Effects on metabolism, specifically hyperkalemia (elevated serum potassium), and gastrointestinal issues like diarrhea are also commonly listed in official documents.

Uncommon reactions span systems including the cardiovascular (e.g., hypotension, palpitations), respiratory (cough), and dermatological systems (rash, urticaria).

Serious Adverse Reactions and Safety Constraints

Regulatory documents identify certain effects as Rare or Very Rare but clinically significant. These serious adverse reactions include anaphylactic reaction, angioedema (swelling of the face or throat), and hepatitis (inflammation of the liver). Changes in renal function are also noted as a risk, particularly in patients with specific pre-existing conditions.

Official labeling contains major, non-advisory safety constraints for specific populations. Use during the second and third trimesters of pregnancy is associated with the risk of fetal injury and death and is a critical restriction. Furthermore, use is generally contraindicated in patients with documented severe hepatic impairment due to potential increases in drug exposure. Symptomatic hypotension is noted as more frequent at the start of treatment or during dose adjustment in vulnerable patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Alderan (Losartan potassium) defines overdose primarily by the risk of profound hemodynamic instability due to its blood pressure-lowering effect. Documented manifestations of overexposure include severe hypotension (excessively low blood pressure) and related signs like dizziness, as well as heart rhythm changes such as tachycardia (fast heart rate) or, less commonly, bradycardia (slow heart rate).

Severe outcomes may include sustained low blood pressure leading to potential end-organ damage, hyperkalemia (high potassium levels), and the risk of acute renal failure in susceptible individuals. The labeling explicitly states that no specific antidote is known for Losartan.

Regulators mandate that treatment for overdose must be symptomatic and supportive, focusing on maintaining blood pressure and renal perfusion. Hospital monitoring is required, as the drug and its active metabolite cannot be removed by hemodialysis.

Immediate medical attention or contact with emergency services is required upon suspected overdose or the manifestation of severe symptoms. Urgent help is explicitly necessary for the sudden onset of swelling of the face, lips, throat, or tongue (angioedema), difficulty breathing, or fainting (syncope).

Therapeutic Uses of Alderan

What Alderan Treats: Main Uses and Benefits

Alderan (Losartan potassium) is commonly used in situations involving chronic conditions to help address symptoms linked to organ-specific functional stress. Its therapeutic benefit is generally centered on stabilizing internal physiological stress, and its benefit is primarily associated with the management of chronic systemic imbalance. The medication is relevant for easing challenging symptomatic phases across three major therapeutic domains: the management of systemic hypertension in adults and children, supportive therapy for chronic heart failure, and the specific addressing of diabetic nephropathy in patients with concurrent Type 2 Diabetes and high blood pressure.

In clinical settings, it is often applied when symptoms create noticeable functional strain and long-term supportive management is appropriate. It is relevant for managing symptoms that interfere with daily comfort and supports general well-being during symptomatic phases.

“This medication is applied across domains where additional symptomatic support is needed, contributing to improved comfort during periods of heightened physiological stress.”


Quick Fact: Management of Chronic Systemic Imbalance

This therapy helps address groups of symptoms that may appear suddenly or fluctuate. It provides supportive relief when symptoms interfere with routine activities associated with sustained high blood pressure.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

The eligibility for Alderan (Losartan potassium) is strictly defined by regulatory guidelines, outlining specific populations who are permitted to use the medicine and those for whom use is prohibited or restricted.


Populations for Whom Use is Contraindicated

Alderan must not be used by patients who fall into these categories, as established in official labeling:

  • Patients with known hypersensitivity to Losartan or any of the product's components.
  • Women in the second and third trimesters of pregnancy due to the high risk of fetal injury.
  • Patients with severe hepatic impairment (severe liver disease).
  • Patients with diabetes or renal impairment who are concomitantly taking a medicine containing Aliskiren.

Age and Condition-Based Restrictions

Category Eligibility Rule Regulatory Status
Pediatric Use Approved for children aged 6 years and older for hypertension. Not recommended for children under 6 [EMA/FDA]. Allowed / Not Recommended
Pregnancy Contraindicated in the 2nd and 3rd trimesters. Not recommended in the 1st trimester [FDA/EMA]. Contraindicated / Not Recommended
Hepatic Impairment Contraindicated in severe cases. A lower starting dose is required for mild-to-moderate impairment [FDA]. Contraindicated / Restricted
Volume Depletion Must be corrected prior to initiation (e.g., in patients on high-dose diuretics) [FDA]. Conditional Use
Lactation Not recommended while breastfeeding [FDA/EMA]. Not Recommended

These rules govern who can safely initiate treatment and under what specific organ function or physiological state limitations.

What should I know about interactions with other medicines?

Alderan Interactions with other medicines and products

Contraindicated Combination and Population-Specific Restrictions

Co-administration with Aliskiren is formally contraindicated in patients with concurrent diabetes or renal impairment. This regulatory restriction is due to the increased risk of adverse outcomes, including hyperkalemia and renal complications, from dual blockade of the Renin-Angiotensin System (RAS).


Pharmacodynamic and Metabolic Interactions

The official profile highlights agents that increase serum potassium levels, such as potassium supplements and salt substitutes containing potassium. Co-administration results in an additive effect that increases the risk of hyperkalemia. Furthermore, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may attenuate the desired antihypertensive effect and increase the risk of renal impairment, particularly in volume-depleted patients. The label also specifies that Lithium clearance is reduced by Alderan, leading to an increased risk of toxicity.


Exposure Modification

A documented pharmacokinetic interaction exists with cytochrome P450 (CYP) enzymes. The CYP2C9 inhibitor Fluconazole increases the systemic exposure (AUC) of Losartan while reducing the exposure of its active metabolite. Conversely, the CYP inducers Rifampin and Phenobarbital reduce the systemic exposure of both Losartan and its active metabolite. Patients with hepatic impairment are noted to exhibit significantly increased Losartan plasma concentrations, which may amplify these pharmacokinetic interaction effects.

Mechanism of Action

Alderan is a human IgG2 monoclonal antibody designed to selectively target the Receptor Activator of Nuclear Factor kappaB Ligand (RANKL). This molecular target is a crucial cytokine necessary for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.

The mechanism of action involves Alderan binding to and sequestering soluble and membrane-bound RANKL with high affinity. This binding prevents the natural interaction of RANKL with its receptor, RANK (Receptor Activator of Nuclear Factor kappaB), located on the surface of pre-osteoclasts and mature osteoclasts.

The resulting blockade disrupts the RANKL/RANK signaling pathway, leading to a cascade effect that suppresses osteoclastogenesis and significantly decreases the bone-resorbing activity of existing osteoclasts. The pharmacodynamic consequence is the modulation of the ratio of bone resorption to bone formation within the skeletal remodeling unit, thus influencing bone turnover kinetics.

Dosage and Administration Information

How to Use Alderan

The administration of Alderan (Losartan potassium) is governed by specific instructions outlined in labeling, defining the standardized approach to its use. It is strictly an oral medication, typically supplied as film-coated tablets in strengths including 25 mg, 50 mg, and 100 mg.


Administration Pattern and Context

The standard protocol for use is once daily, and the tablet can be taken with or without food. If a dose is missed, it should be taken as soon as possible, but strictly avoid taking a double dose to compensate for the skipped one.


Standardized Dosing Regimens

Dosing regimens differ based on the chronic condition being addressed.

Indication Typical Starting Dose Maximum Daily Dose Special Conditions
Systemic Hypertension 50 mg once daily 100 mg once daily Twice-daily dosing may be employed if necessary to maintain effect.
Chronic Heart Failure 12.5 mg once daily 150 mg once daily Dose is titrated upward at weekly intervals (e.g., 12.5 mg

ightarrow 25 mg ightarrow 50 mg). |


Population-Specific Adjustments

In specific patient populations, a lower initial dose of 25 mg once daily is designated. This adjustment is necessary for individuals with hepatic impairment (mild-to-moderate) or those who are intravascularly volume depleted, such as patients receiving high-dose diuretic therapy. For pediatric patients (ge 6 years), the starting dose is 0.7 mg/kg once daily. The maximal antihypertensive effect is typically achieved over three to six weeks of consistent daily application, confirming its role in long-term management.

Recent Clinical Evidence

The evidence base for Alderan (Losartan potassium) is derived primarily from large-scale Randomized Controlled Trials (RCTs) focusing on three main indications evaluated for regulatory approval.

Evidence for Use in Managing Systemic Hypertension

Studies were conducted to evaluate changes in Systolic and Diastolic Blood Pressure (SBP/DBP) in both adults and pediatric patients aged 6 and older. Longer-term trials monitored the occurrence of major cardiovascular events. Findings consistently reported measured changes in blood pressure. However, some studies documented a smaller blood pressure effect observed in Black patients compared to other groups, and long-term data for the highest dose levels in children remain limited.

Evidence for Use in Diabetic Nephropathy

For patients with Type 2 Diabetes and concurrent hypertension, long-term, placebo-controlled RCTs were conducted. Research focused on outcomes reflecting the progression of kidney disease, such as the doubling of serum creatinine or the need for dialysis (End-Stage Renal Disease). Studies reported how these functional measures changed over observation periods extending several years. Evidence is limited for individuals without concurrent hypertension and those with the most severe kidney function impairment.

Evidence for Use in Chronic Heart Failure

Alderan was evaluated in research involving adult patients with heart failure who are unable to use standard first-line therapies. The studies tracked critical outcomes, including death from any cause and hospitalization for heart failure exacerbation, as well as changes in functional status. Certainty remains low for use in patients with the most advanced functional limitations (NYHA Class IV).

Overall, the research highlights that while long-term data exist for primary outcomes, information for certain specialized populations and subgroups remains limited.

Frequently Asked Questions (FAQ)

Common questions about Alderan (FAQ)


Q: How quickly do people typically notice a change after starting Alderan?

According to official product information, the blood pressure lowering effect of Alderan is often substantially present within approximately one week of beginning treatment. The maximum desired therapeutic effect usually takes longer, generally being achieved over three to six weeks of consistent daily application.


Q: Can Alderan affect my sleep patterns?

Official labeling documents list several nervous system-related adverse reactions, including common effects like fatigue and asthenia (a feeling of weakness or lack of energy). While these effects are related to energy levels, specific changes to sleep patterns are not universally listed across major safety profiles.


Q: Are there any common over-the-counter medicines that are known to interact with Alderan?

Regulatory documents highlight that a class of over-the-counter medicines known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may interact with Alderan. Using these together can potentially reduce the desired antihypertensive (blood pressure lowering) effect and may increase the risk of certain changes in kidney function.


Q: Can I take ibuprofen or aspirin with Alderan?

Ibuprofen and aspirin belong to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official safety information indicates that NSAIDs may interact with Alderan by potentially increasing the risk of adverse effects on renal (kidney) function and lessening the blood pressure effect.


Q: Can Alderan be used by people who have diabetes?

Yes. According to official indications, Alderan is approved for use in patients with Type 2 Diabetes who have concurrent hypertension and kidney disease (diabetic nephropathy), as a way to slow the rate of disease progression. A regulatory restriction (contraindication) exists for diabetic patients who are also taking a medicine containing Aliskiren.


Q: Does Alderan have a Black Box Warning from the FDA?

Yes, the official U.S. labeling contains a Boxed Warning. This is the most serious warning for prescription medicines and is related to the use of Alderan during the second and third trimesters of pregnancy, due to the significant risk of fetal injury and death.


Q: Can Alderan cause vision changes or blurred eyesight?

Vision changes, such as blurred vision, are not typically listed as a common direct side effect. However, they have been reported as a symptom of hypotension (low blood pressure), which is a known risk, particularly when treatment is started or a dose is adjusted.


Q: What are the symptoms of an allergic reaction to Alderan?

Serious, rare allergic reactions listed in regulatory documents include anaphylactic reaction and angioedema. Angioedema is often described in patient information as swelling of the face, lips, tongue, or throat.


Q: Does taking Alderan make you feel tired or drowsy?

Official safety documents list fatigue (lack of energy) and asthenia as commonly reported adverse reactions. Additionally, dizziness and low blood pressure may contribute to a feeling of tiredness or low energy.


Q: Is Alderan considered a controlled substance?

Alderan (Losartan potassium) is a medicine that requires a prescription. However, it is not classified as a federally controlled substance by major regulatory bodies. Controlled substances are those with a recognized potential for abuse or dependence.


Q: Can Alderan be crushed, split, or chewed?

Alderan is supplied as a film-coated tablet. Regulatory documents for some tablet strengths state that the tablet can be divided into equal doses, suggesting it can be split along a score line. However, official guidance does not typically advise crushing or chewing the tablet.


Q: Is Alderan meant to be a short-term or long-term medication?

Alderan is generally intended for the long-term management of chronic cardiovascular conditions. Its maximal therapeutic effect is reached over several weeks of consistent use.


Q: How does Alderan affect blood pressure or heart rate?

The intended function of Alderan is to achieve an antihypertensive effect, meaning it lowers blood pressure. While it is not primarily a heart rate medicine, the official safety profile notes adverse effects including palpitations (a change in heart rhythm) and hypotension (low blood pressure).


Q: Is there a generic version of Alderan available? / Are generic and brand-name Alderan exactly the same in terms of effect?

Alderan is the brand name for the active ingredient Losartan potassium, and generic formulations containing Losartan potassium are available. Regulatory agencies require that generic and brand-name formulations meet standards for bioequivalence, meaning they must work in the body in essentially the same way.


Q: Can I take Alderan while consuming alcohol?

Official labeling does not list a specific contraindication for the combined use of Alderan and alcohol. Both the medicine and alcohol may cause similar effects, such as dizziness and headache.


Q: Are there any dietary restrictions I need to follow while on Alderan?

The official safety profile specifically notes a potential interaction with potassium supplements and salt substitutes that contain potassium. This is due to an increased risk of elevated serum potassium levels (hyperkalemia) when used together with Alderan.


Q: Is Alderan safe for older adults (seniors)?

The official label does not list advanced age as a specific contraindication for use. However, a lower starting dose is often initiated for patients who have certain conditions common in the elderly, such as hepatic impairment (liver disease) or volume depletion.


Q: Are there studies about Alderan's use in children or teenagers?

Yes. Official documents indicate that Alderan is approved for the treatment of hypertension in pediatric patients aged 6 years and older. Its effectiveness and safety have not been established in children under 6 years of age.


Q: How is Alderan typically stored (room temperature, fridge, etc.)?

Alderan is generally required to be stored at a Controlled Room Temperature, which is the standard regulatory requirement for many medications. It should be kept in a secure location and protected from moisture and heat to maintain its quality.


Q: What should I do if I experience a severe or unexpected side effect from Alderan?

Reporting mechanisms exist for severe or unexpected effects. Suspected adverse reactions can be reported directly to the medicine's manufacturer or through official regulatory reporting programs like the FDA's MedWatch program.


Q: How long does Alderan stay in your system after the last dose?

The duration Alderan remains in the system is described by its half-life. The active substance has a terminal half-life of approximately 1.5 to 2.5 hours, and its more active metabolite has a half-life of 6 to 9 hours.


Q: Is Alderan available as an injection, liquid, or only a tablet/capsule?

Alderan is primarily available as a film-coated tablet for oral use. In addition to the tablet, an oral suspension (liquid) formulation of Losartan potassium is also available.


Q: Does Alderan affect the results of common lab tests?

Regulatory documents note that the use of Alderan results in an increase in plasma renin activity (PRA). Changes to serum potassium and renal function measures (like creatinine) are also potential effects noted during treatment.


Q: Is Alderan known to cause stomach upset or nausea?

Gastrointestinal issues are listed among the documented adverse reactions. Diarrhea is commonly listed in official documents, and nausea and gastritis (stomach inflammation) are also noted in the safety profile.


Q: What are the official guidelines for driving or operating machinery while on Alderan?

No specific studies on the effects of Alderan on the ability to drive and use heavy machinery have been specifically performed. Caution is generally advised because of the possibility of adverse effects like dizziness or fatigue, which could affect alertness.


Q: Does Alderan need a special prescription (like a triplicate form)?

Alderan is classified as a prescription-only medicine. Because it is not classified as a federally controlled substance, it does not typically require the specialized prescription forms, such as triplicate forms, that are mandated for controlled drugs.


Q: Is there a patient brochure or official website for Alderan?

Yes. Official documents such as the Patient Information Leaflet (PIL) or equivalent patient labeling are created and reviewed by regulatory agencies and manufacturers to provide authorized, factual information about Alderan to the public.


Q: Do official sources mention any risk of dependence with Alderan?

Official regulatory documents and classifications do not indicate a risk of physical or psychological dependence or substance abuse with Alderan (Losartan potassium).


Q: What makes Alderan different from older drugs for the same condition?

Alderan (Losartan potassium) is an Angiotensin II Receptor Blocker (ARB). Official descriptions note that it differs from older classes, such as ACE inhibitors, by acting through direct receptor blockade of AT₁ receptors, rather than by enzymatic inhibition.

How should Alderan be stored and disposed of?

Official Storage and Disposal Guidelines

Prescription medications are regulated to require storage at specific environmental conditions to maintain quality and potency. If no specific label instruction is present, drugs are typically required to be stored at a Controlled Room Temperature.

Containers must remain intact and provide adequate protection from the surrounding environment. To prevent the risk of accidental ingestion, all medicine must be stored in a secure location inaccessible to children.

Disposal must adhere to regulatory guidelines to prevent environmental contamination and diversion. The safest and preferred method of disposal is through an official drug take-back program. If a take-back program is unavailable, the medicine can be prepared for household trash by mixing it with an unpalatable substance (such as dirt or cat litter) and sealing it in a container prior to discarding. Personal information on labels must be thoroughly obscured before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alderan found in:

A-Z Index: